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Abstract
Background: Despite physicians’ increasing knowledge regarding heart failure (HF),
a significant percentage of patients still do not receive adequate treatment. The aim of this
multicentre, retrospective descriptive study was to reveal the pharmacotherapy patterns in HF
patients hospitalized in cardiology (CARD) and internal medicine (INT) wards in Poland.
Methods: Included into the study were 800 consecutive patients who were admitted to the
hospitals: 350 patients from 7 CARD wards and 450 patients from 9 INT wards.
Results: The average age in the study group was about 70 years (youngest participant under
40 and oldest at 95 years of age). Decompensation of HF or acute HF were the most frequent
causes of hospitalization (in both groups > 50%). The main etiology was coronary artery
disease, either alone or together with hypertension (from about 60% in INT patients to about
78% in CARD patients, p = NS). With regard to pharmacotherapy, angiotensin converting
enzyme inhibitors were used in 81% of cases (77% CARD and 83% INT; p = 0.05); out of this
group, doses were at optimal or larger in 39.3% of patients (38% CARD patients and 39.4%
INT patients). Beta-blockers were administered in 31.4% and 19.1% of patients from the
CARD and INT groups respectively (p<0.0001), but optimal dosing was negligible.
Conclusions: Compared with an assessment conducted several years ago, the past education
initiatives have significantly improved the quality of standard-based HF treatment. However,
suboptimal dosing and the use of drugs that do not improve prognosis remain an unresolved
issue in this population. (Cardiol J 2008; 15: 169–180)
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Introduction
Heart failure (HF) is an important clinical and
social problem with high morbidity and mortality
rates. Coronary artery disease and arterial hyper-
tension are the most common causes of HF, whe-
reas primary or secondary cardiomyopathy and he-
art defects are less frequent. Incidence of HF in the
general population is estimated at 0.4% to 2% [1],
thus it must be assumed that 700,000 patients in
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Poland are affected. The aging of the general popu-
lation and advances in cardiovascular disease tre-
atment lead to a gradual increase in the HF popula-
tion. It is believed that 90% of the new cases are
people over 60 and the majority of this population
is made up of elderly subjects. The increasing num-
ber of HF patients means an increasing percentage
of patients requiring intensive medical care as well
as an increase in hospitalization rates. European and
American data indicate a twofold increase in the rate
of hospitalizations due to CHF within the last
10–15 years, and the rate of re-hospitalizations within
the period of 3–6 months in elderly CHF patients
has reached 29–47% [2]. Therefore, it is not sur-
prising that treatment costs in HF patients make
up approximately 1–2% of the entire healthcare
budget in developed countries [3].
Numerous clinical studies conducted during
the last two decades have confirmed the beneficial
effect of angiotensin converting enzyme inhibitors
(ACEI), beta-blockers (BBs), spironolactone and
sartans in the HF population [4–9]. Based on these
studies, scientific and national guidelines regarding
management of HF patients, including recommen-
ded pharmacotherapy, have been developed [10, 11].
However, despite the expanding knowledge of phy-
sicians regarding HF, bibliographic data indicates
that a significant percentage of this population do
not receive treatment of proven beneficial effect on
prognosis. It is unknown whether non-optimal tre-
atment in HF patients from the general population
is a consequence of the selection of participants for
clinical studies or due to poor compliance of ambu-
latory physicians with published guidelines. Inconc-
lusive opinions result from the scarcity of reliable
data regarding the pharmacotherapy and prognosis
in HF patients from the general population, parti-
cularly from hospital health settings.
The aim of this study was to obtain informa-
tion regarding the most common pharmacotherapy
methods in HF patients admitted to hospitals (re-
ference level I or II) in Poland, with particular at-
tention being paid to ACEI and BBs, as well as ob-
taining the characteristics of the in-patient popula-
tion diagnosed with HF, hospitalized in internal and
cardiology wards.
Methods
Study design and population characteristics
This was a multicentre retrospective cross-
country descriptive study, conducted by 16 investi-
gators from 16 randomly selected centres from the
hospital database, including 9 internal medicine
(INT) and 7 cardiology (CARD) wards (reference
level I or II) throughout Poland. With respect to
entry criteria, all patients included in study had to
have systolic heart failure diagnosis based on ob-
jective verification (in accordance with 2001 Euro-
pean Cardiology Society guidelines — an objective
confirmation of systolic dysfunction was required)
documented in medical records in the past or during
analysed hospitalization. Fifty consecutive patients
with a confirmed diagnosis of HF, admitted within
the 6 months preceding the study, were included by
each investigator regardless of the primary cause of
hospitalization (the most recent hospitalization).
A heart failure patient hospitalization questionnaire
was filled out for each patient, which consisted of four
parts: general information on the hospital and ward,
detailed information — about the patient, hospitali-
zation course and medical history, and detailed in-
formation on the use of both ACEI and BBs.
Statistical analysis
All statistical analyses were conducted at the
Office of Biostatistics in the Department of Epide-
miology and Cardiovascular Disease Prevention of
the Institute of Cardiology in Warsaw. All statisti-
cal analyses were performed using SAS v 8.2 so-
ftware (SAS Institute, Cary, NC).
Our statistical analysis included demographic
and clinical variables obtained from questionnaires,
especially the number and duration of hospitaliza-
tions and HF pharmacotherapy, both prior to and
during the analyzed hospitalization. For the purpo-
se of this study, the a level of significance was set
at 5% for all statistical calculations. Depending on
the normal distribution and the number of groups
compared, the following tests were used for the qu-
antitative variables: Student’s t-test, Mann-Whitney
test, analysis of variance and Kruskal-Wallis test. For
qualitative variables we used the c2 test and Fisher’s
exact test. An assessment of relationships between
study variables was performed by Pearson, Spear-
man, and Cramer correlation coefficients.
Results
The final analysis was based on data from 800
patients diagnosed with HF, hospitalized between
October 2002 and April 2003. There were 350
CARD subjects and 450 INT patients.
Population characteristics
Demographic and clinical data are presented in
Table 1. The gender distribution in the two hospi-
tal population subsets was alike. The average age
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in the study population was approximately 70 years,
with the youngest patient under 40 and the oldest
95 years old. The body mass index (BMI) was si-
milarly elevated in both groups, without significant
difference. Systolic blood pressure was elevated in
the entire population, especially in INT patients.
Among all patients, decompensation of HF or acu-
te HF were the most common causes of index ho-
spitalization and rates were similar in both groups,
exceeding 50%. Other cardiac causes of hospitali-
zation included acute coronary syndromes, in ap-
proximately 25% of CARD patients, with lower fre-
quency in INT patients. Extra-cardiac hospitaliza-
tion causes made up only a small portion (2%) of
CARD, but almost 13% of INT admissions. Out of
the study population, 34.9% CARD and 33.1% INT
patients reported hospitalization for cardiovascular
reasons within the 12 months preceding the study.
On the other hand, 47.7% and 32.9% patients, re-
spectively, did not confirm hospitalization due to
cardiovascular reasons, with no data for 17.4% of
CARD patients and 34% of INT (p < 0.0001).
Etiology, diagnosis and progression
of heart failure and concomitant diseases
Coronary artery disease, either alone or toge-
ther with arterial hypertension, were the most com-
mon etiology of HF in both groups; however, they
differed significantly with this regard (Fig. 1).
In most cases heart failure was diagnosed be-
fore the index hospitalization (46.3% CARD vs. 44%
INT) although there were no data for a substantial
proportion of the patients: 40% vs. 21.1% (p <
< 0.0001) for INT and CARD, respectively. With
regard to diagnostic examinations, 53.2% of patients
had an echocardiogram performed during the ana-
lyzed hospitalization, more frequently in CARD
(73.1%) compared with INT (54.8%; p < 0.0001).
In subjects who underwent an echocardiographic
examination, only 40% from the CARD group (data
Table 1. Study population characteristics.
Parameter Cardiology Ward Internal medicine ward Total
(n = 350)  (n = 450)  (n = 800)
Gender (% males) 50.9% 45.8% 48.0%
Age (range) (years) 69.1 ± 10.8 (37–95) 71.1 ± 10.0 (43–94) 70.2 ± 10.4 (37–95)
Body mass index > 25 (%) 88.1% 83.4% 85.1%
Systolic blood pressure [mm Hg]* 146.0 ± 30.7 151.8 ± 33.5 149.3 ± 32.4
Diastolic blood pressure [mm Hg] 87.4 ± 17.3 89.8 ± 17.3 88.7 ± 17.3
Heart rate [min–1] 97.7 ± 28.6 95.1 ± 25.1 96.3 ± 26.7
Smokers (%)** 27.7% 18.4% 22.5%
Average hospitalization (days) 11.0 ± 5.7 11.6 ± 7.2 11.3 ± 6.6
Data as means ±SD; *p = 0.01; **p < 0.0001; all other p = NS
Figure 1. Distribution of suspected etiology of heart failure.
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for 48% of the whole group) and 46% from the INT
group (data for 42% of the whole group) were fo-
und to have EF £ 40%; p < 0.0001.
The progression of HF was determined by
NYHA classification in 62.9% patients. Patients in
NYHA class III constituted the largest percentage
of patients; however, in 1/3 of CARD patients and
41% of INT the data was lacking. NYHA distribu-
tion was alike in both subpopulations (Fig. 2).
The great majority of patients had comorbidi-
ties (Table 2). Most common was ischemic heart
disease (from about 60% in INT patients to about
78% in CARD patients, the difference being stati-
stically significant). Consequently, arterial hyper-
tension was also diagnosed in over 60% of patients
from both groups; slightly more often in the INT
group. Moreover, diabetes was frequent in the stu-
died populations, reaching 1/3 of the INT group,
whereas renal failure was diagnosed in nearly eve-
ry eighth patient (p = NS); 63.4% of CARD patients
and 73.1% of INT patients were diagnosed with
other, unspecified non-cardiovascular conditions
and the difference was statistically significant.
Pharmacotherapy
Angiotensin converting enzyme inhibitors.
On average, 39.2% of the patients were on ACEI
prior to hospital admission; significantly more in the
CARD group (40.6%) than in the INT group (38%;
p = 0.035). During hospitalization the proportions
of patients receiving ACE inhibitors increased to
83% and 88%, respectively, with discharge rates as
follows: 77% in CARD and 83% in INT (p = 0.05;
81% for the whole population). In the vast majority
of cases (94%) ACEI were not changed during ho-
spitalization, and in the remaining 6%, benazepril
(33%) and captopril (31%) appeared to be replaced
most often. Most frequently drug formulation was
replaced due to economic reasons (33.7%), followed
by inefficiency or poor tolerance of the previous
drug (20.7% and 2.1%, respectively) and other cau-
ses (28.3%). In 32.5% of cases the data was not
available. Figure 3 shows the final distribution of
each ACEI (differences between INT and CARD
were insignificant).
Both in CARD and INT groups, doses of all
ACEI were increased during hospitalization; however,
less than half of the patients received the recommen-
ded dose. Based on hospital discharge cards, an ave-
rage of 39.3% of the patients on ACEI received doses
optimal or larger (38% of CARD and 39.4% of INT
patients). Figure 4 presents the detailed distribution
of ACEI agents. The following factors were pointed
out as the most frequent causes of sub-optimal dose
administration: too short period of drug use (35.9%),
systolic blood pressure < 100 mm Hg (14.1%), lab
test results regarding creatinine and electrolyte le-
vels (5%), a history of poor tolerance to higher do-
ses (4.4%), side effects (1.9%), other causes (1.2%),
and in 37.5% of cases the data was unavailable.
Figure 2. Distribution of NYHA classification in studied
population.
Table 2. Analysis of comorbidity distribution in studied population.
Cardiology Internal Whole
ward medicine ward population
Coronary artery disease with infarction (%) 37.1 32.0 34.3
Coronary artery disease without infarction (%)* 40.9 29.8 34.6
Hypertension (%) 65.4 71.1 68.6
Supraventricular arrhythmia (%)* 53.7 36.0 43.8
Ventricular arrhythmia (%)* 16.6 7.8 11.6
Diabetes (%) 27.7 33.1 30.8
Renal failure (%) 14.3 10.9 12.4
Hyperlipidemia (%)* 26.3 14.0 19.4
Other diseases, non cardiovascular (%)** 63.4 73.1 68.9
*p £ 0.001; **p = 0.003; all other p = NS
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Of the patients who did not receive ACEI tre-
atment at discharge, 5.6% of subjects either had
begun to receive the drug during hospitalization or
had been taking the drug prior to hospitalization and
the treatment was later discontinued. There were
14.6% of patients not receiving ACEI during hospi-
talization. The reasons for not prescribing ACEI
during hospitalization or for treatment discontinu-
ation are presented in Figure 5.
Beta-blockers. As in the case of ACEI, BB
administration was found to be more prevalent
among CARD patients than INT patients (31.4% vs.
19.1%, respectively; p < 0.0001). Beta-blockers tre-
atment was initiated in a significant percentage of
patients during hospitalization; thus the ratio of
patients on BBs increased to 61.7% and 50.4%, re-
spectively (p = 0.0015). In 13.5% of patients, BB
was replaced by another drug from the same class
Figure 3. Frequency of angiotensin-converting enzyme inhibitor administration.
Figure 4. Optimal dosing of angiotensin-converting enzyme inhibitors; *optimal dose of each drug.
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ACEI, the doses of all BBs were increased during
hospitalization, both for CARD and INT. An analy-
sis of BB doses approved for HF treatment showed
that only a marginal proportion of patients received
optimal dosing. The rates for EVBM BBs for CARD
and INT were as follows: bisoprolol (10 mg) 6.4%
and 3.3%, metoprolol (both tartrate and succinate,
e.g. in a dose of 100 mg) 21% and 17%, and carve-
dilol (50 mg) 0% in both groups.
Of the patients with no BBs at discharge, 5.1%
either had began receiving the drug during hospi-
talization or had been taking the drug prior to ho-
spitalization and the treatment was later disconti-
nued. There were 44.5% of patients not receiving
BBs during hospitalization. The reasons for not
prescribing BBs during hospitalization or for treat-
ment discontinuation are presented in Figure 7.
At discharge 46.6% CARD and 37.8% INT pa-
tients (41.6% on average) received a combination
of both ACEI and BBs.
Other drugs used in heart failure. Diure-
tics were used in approximately 1/3 of cases (35.1%
of CARD patients and 32% of INT patients; p = NS);
however, at discharge the ratio increased to 85.1%
and 87.3%, respectively (p = NS). Interestingly,
71.1% of CARD and 82.8% of INT patients requ-
ired intravenous diuretic treatment during the ana-
lyzed hospitalization.
Oral furosemide was the most commonly used
diuretic in both study populations, slightly more
often in the INT, followed by indapamide (at total
doses of 2.5 and 1.5 mg) (Fig. 8). A small propor-
tion of patients in both subpopulations (about 5%)
received concomitant treatment with two diuretics.
Figure 5. Reasons for not giving angiotensin-converting
enzyme inhibitors.
during hospitalization. The most commonly repla-
ced BBs were: propranolol (replaced in 36% of ca-
ses), acebutolol (25%), atenolol (25%), metoprolol
(17%) and sotalol (13%). At discharge from the ho-
spital the percentage of patients treated with BBs
was 55.4% for CARD and 46% for INT (p = 0.008).
It must be stressed, however, that a significant
number of patients still received BBs not approved
for the treatment of heart failure (CARD — 17.1%,
INT — 14.9%). Figure 6 shows the distribution of
BB agents. With respect to dosing, as in the case of
Figure 6. Frequency of beta-blocker administration.
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Figure 7. Reasons for not giving beta-blockers.
During the analyzed hospitalization, a signifi-
cant increase in the frequency of spironolactone use
was also observed: from 15.4% among CARD pa-
tients and 14.4% among INT patients (p = 0.0065)
to 48.3% and 48.7%, respectively. Conversely, the
proportion of patients receiving digitalis increased
from 17.4% and 15.6% (the difference between gro-
ups, p = 0.009), almost twofold.
Among the other drugs used, acetylsalicylic
acid (ASA) (63%) and long-acting nitrates (52%)
were the most frequently reported, the latter class
being significantly more frequent in the CARD group.
Other anticoagulants were recommended in appro-
ximately 41% of cases, also more frequently in the
CARD group. Conversely to the use of ASA, there
was some disproportion in the use of statins, which
were recommended in approximately 29% of cases
(more commonly in the CARD group) (Table 3).
Discussion
This study is a retrospective epidemiological
project describing the characteristics of HF patients
admitted to cardiology and internal medicine wards
Figure 8. Frequency of diuretics administration.
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(first and second level of reference). A group of 800
subjects (with objective confirmation of HF diagno-
sis) were included in the study. This is particularly
important because in most epidemiology studies the
diagnosis was based on clinical criteria. The avera-
ge age of the study population was 70 years and is
consistent with findings from previous reports, in-
dicating that HF is a condition most prevalent in the
elderly population [2, 12, 13].
Baseline population characteristics
Gender distribution in the analyzed population
in both groups was similar, closely resembling that
from the EuroHeart Survey conducted in cardiolo-
gy and internal medicine wards in over 10 Europe-
an countries [13]. In an observational study of am-
bulatory patients from several years ago, the per-
centage of women was slightly greater, reaching
53% [14], and in the IMPROVEMENT studies wo-
men constituted 45% [2]. Thus, it can be assumed
that HF incidence in the Polish population is simi-
lar for both genders.
An interesting issue is the observation of the
occurrence of overweight patients and even obesi-
ty in this population [15], which seems to be a con-
sequence of not only limited exercise tolerance, but
also inadequate patient compliance. Additionally,
the high rate of smokers, higher than in other stu-
dies (13%) [2, 15], seems to support the notion of
insufficient patient cooperation. A relatively con-
sistent finding in the Polish population are eleva-
ted systolic blood pressure values, which in the
IMPROVEMENT study proved to be among the hi-
ghest in Europe, despite a comparable proportion
of hypertension patients [2], and were higher than
in most epidemiology studies [15, 16].
Another clinical issue is the very high average
heart rate, nearly 100 bpm, which reflects the level
of adrenergic system inhibition and treatment effi-
cacy. In other populations the average heart rate did
not exceed 74–76 bpm, but these subject came from
ambulatory settings and were generally in better
clinical condition, something which may explain the
observed differences [12, 15, 16].
The distribution of HF etiologies indicating the
main role of coronary artery disease followed by
arterial hypertension corresponds with the data for
the European population [17] as well as with the
results from a population study conducted by Ry-
wik et al. [14]. However, it is believed that soon,
due to advances in the treatment of acute myocar-
dial infarction, arterial hypertension, currently li-
sted as the second most common cause of HF, will
become the most common.
Considering the specific character of the HF
population, the vast majority of cases report nume-
rous comorbidities, which, apart from making the
optimal pharmacotherapy difficult, often adversely
influence prognosis increasing the risk of rehospi-
talisation [18]. In our population, as in the EuroHe-
art study, cardiovascular diseases (coronary artery
disease and arterial hypertension) were the most
common concomitant diseases, observed most often
in the CARD group and determined by the charac-
teristics of these wards. The high prevalence of
supraventricular arrhythmias (reported in nearly
half of CARD patients and in approximately 1/3 of
INT patients) is probably a result of the inclusion
Table 3. Frequency of drug administration
Medicine classes Cardiology ward Internal medicine ward
(% of patients in the group)  (% of patients in the group)
Sartans 2.0% 1.1%
Long acting nitrates 61.6% 44.2%
Short acting nitrates or molsidomine 32.0% 29.6%
Digitalis 27.7% 30%
Calcium antagonists** 27.7% 16.1%
Alfa antagonists 2.3% 1.1%
Acetylsalicylic acid 63.7% 61.8%
Antiarrhythmic agents* 25.4% 16.7%
Other anticoagulants* 47.8% 35.9%
Statins* 35.4% 23.8%
Fibrates 1.1% 1.3%
Non-steroidal anti inflammatory drugs (NSAID) 10.1% 14.2%
*p < 0.01, **p < 0.0001, all other p = NS
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of arterial fibrillation into this category, which is
common in the course of HF [13, 16, 17].
Other frequent non-cardiovascular diseases
included diabetes and renal insufficiency, which were
also shown in earlier population studies [13, 17],
a fact that should be taken into consideration while
selecting pharmacotherapy, especially with regard
to the use of rennin-angiotensin-aldosterone sys-
tem inhibitors.
Rehospitalisation is frequent among the HF
population, with an event rate ranging from less
than twenty up to at least 1/3 during a years’ obse-
rvation [19, 20]. Moreover, as was observed in
a Swedish population study, hospitalization due to
cardiovascular reasons [16] is an unfavourable pro-
gnostic factor. Of the studies conducted so far,
which have analyzed the causes of hospitalization,
the most complete information comes from the
EuroHeart Survey [13]. Similarly to our results, the
data for the Polish population from EuroHeart Su-
rvey shows that the most common cause of analy-
zed hospitalization was HF decompensation, both
for cardiology or internal medicine departments.
This indicates the importance of popularization
of HF issues among general practitioners/internal
medicine specialists, as HF is becoming a problem
extending beyond the cardiology field, also with
regard to in-patient treatment. Differences concer-
ning acute coronary syndromes are likely due to
administrative reasons and better preparation to
handle this group of patients at CARD wards.
It is somewhat surprising that EF £ 40% was
observed in less than 50% of patients, both in the
CARD and INT groups. This situation is probably
a consequence of the study methods, which accep-
ted objective verification of systolic dysfunction do-
cumented prior to study inclusion. Thus, it cannot
be excluded that in some cases of acute cardiova-
scular episode (acute coronary syndrome, myocar-
ditis, tachycardia, etc.) there was an improvement
in left ventricular systolic function after the appro-
priate treatment was administered. Another factor
that should be taken into consideration while inter-
preting the presented results is the very small pro-
portion of patients with actual available objective as-
sessment of cardiac systolic function. Similar discre-
pancies have been reported in other studies, in
which systolic dysfunction was assessed according
to protocol. This includes the IMPROVEMENT
study [2], in which EF < 40% was observed in ñ of
the patients and the EuroHeart study [13] with com-
parably low EF values (in 51% of men and only 28%
of women).
Pharmacotherapy
The data unequivocally indicates that hospita-
lization of HF patients resulted in an improvement
in treatment quality. An increase in the administra-
tion of ACEI (up to 80.5%) and BBs (50.1%) was
recorded in all groups, being more pronounced in
the INT. The percentage of the general population
diagnosed with HF and treated with ACE inhibitors
ranged from 44% in the American study from the
early 90 s [21] to approximately 60% in both the
IMPROVEMENT and a Polish population study [22].
Hence, the most recent publications indicate an
increase in the use of these drugs in up to approxi-
mately 80% of cases [12]. On the other hand, the
data on hospitalized patients indicates that the fre-
quency of ACEI administration was close to 60% in
the EuroHeart study, reaching as much as 100% for
patients treated in cardiology wards [23]. In most
publications, treatment by a cardiologist increased
the likelihood of receiving ACEI [23]. Our study
showed contrary results, a trend which was also
observed in an Italian study [17].
Most authors did not analyze the causes of
ACEI treatment discontinuation, except for data
indicating age and comorbidities as factors reducing
the chances of receiving drugs from this class. In
the analyzed group about 20% of patients had con-
traindications for their use, comparable to previo-
us reports [24]. It must be stressed, however, that
in most cases hypotension could be iatrogenic, re-
sulting from the use of other drugs affecting syste-
mic blood pressure. Only a few studies analyzed
doses for this class of drugs in relation to guideli-
nes [2, 23–25]. Both in the IMPROVEMENT and
EuroHeart studies, the vast majority of subjects were
on drug doses lower than recommended [2, 25]. The
presented results, showing that nearly 40% of pa-
tients received optimal doses (both internal medi-
cine and cardiology wards), seem to be among the
highest, although far from what was expected. It is
noteworthy that only two of the ACEI used (perin-
dopril and quinapril) were administered to most of
the patients (at least 2/3 of the study population) in
the recommended doses.
A comparison with previous population studies
shows unequivocally a continuous tendency to pre-
scribe BBs too rarely and in insufficient doses. This
is likely to be the cause of differences between po-
pulations from clinical studies and actual HF pa-
tients from the general population. The efficacy of
BBs in the aged population of HF patients has been
confirmed only recently [26]. However, the results
of interesting work by Lenzen et al. [27] indicate
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that, even in a population comparable with the cli-
nical study population, BBs are used too rarely and
in inadequate amounts. In the previously mentio-
ned study by Rywik et al. [22], drugs of this class
were used in approximately 20% of patients, in
EuroHeart — in about 37% and in the Italian popu-
lation in less than 10% in subjects from internal
medicine up to 20–40% in patients from cardiology
wards [23, 24]. Thus, our results indicate an impro-
vement in treatment quality. Simultaneously, the
proportion of patients receiving both ACEI and BBs
has increased since the earlier data in both subgro-
ups [22, 25]. An important observation, reported in
the EuroHeart study and in our material, is the high
proportion of patients (15%) classified as receiving
BBs who in fact received agents of which the effi-
cacy was not confirmed in the HF population [25].
The small proportion of BB recipients in most stu-
dies regarding hospitalized patients may be the re-
sult of HF decompensation as the main cause of
admission, consequently leading to a delay in the
initiation of treatment. The reasons given as the
main cause of drug discontinuation confirm the re-
maining lack of physicians’ experience, especially
with regard to the management of patients in ad-
vanced stages of the disease. Additionally, the pre-
viously mentioned high average heart rate sugge-
sts insufficiently intensive BB treatment.
As reported by other authors [17, 22, 24, 25],
the high prescription of diuretics in both subgroups
is easily justified by the patient distribution (main-
ly NYHA classes III and IV, with coexisting hyper-
tension). The greatest changes in pharmacothera-
py were noted for spironolactone, as there was
a threefold increase in the use of this drug in both
subgroups during hospitalization, and there use is
definitely greater than several years ago [2, 22, 25].
The popularity of spironolactone indicates that the-
re is little concern over its use in the HF popula-
tion, despite narrow indications and the possibility
of hyperkalemia-related complications [10].
A little over a decade ago digitalis was the drug
of choice in HF, but at present, according to cur-
rent guidelines, it should be instituted only in ad-
vanced HF or in the early stages as a heart rate
control therapy. In comparison with earlier data for
the Polish population [2, 25] digitalis was used in
approximately every third patient.
Due to the large percentage of patients with
ischemic heart disease (over 60%), a considerable
proportion of patients would be expected to rece-
ive statin treatment. Our results are surprising from
this perspective. Moreover, the type of hospital did
not affect the treatment. In most studies statin pre-
valence was not recorded; nevertheless, in one of
them (the TEMISTOCLE study) the prescription
rate was significantly higher, reaching up to 70%
for cardiology wards and approximately 40% in in-
ternal medicine wards [17]. Considering the results
of the most recent studies, indicating the benefi-
cial effect of this class of drugs in the HF popula-
tion [28, 29], future publications are likely to report
a significantly higher number of patients receiving
statin treatment. On the contrary, acetylsalicylic
acid was used in about 2/3 of the population witho-
ut differences between groups, whereas long-acting
nitrates were used more often in the CARD popu-
lation — a consequence of the clinical characteristics
of this group of patients. The latter class of drugs,
without proven beneficial effects on prognosis (used
without combination with dihydralazine), is one of
the most commonly used in the majority of studies
[17, 22, 24, 30]. In Poland their use is 1.5 fold higher
than in other countries. Another constant trend for
the Polish population is a significant number of pa-
tients receiving calcium channel blockers, higher
than in other European studies [17, 30–32]. None-
theless, it has been cut by almost fifty percent com-
pared to a study conducted several years ago [22].
Limitations of the study
This is a retrospective observational study. As
entry criteria, with respect to systolic heart failu-
re, were based mainly on medical records from the
past, they might not always be unambiguous within
the studied population. Another aspect, which sho-
uld taken into consideration, is the study period,
which covered the years 2002–2003, thus it cannot
be excluded that the present situation slightly dif-
fers from that described.
Conclusions
The presented results, to our knowledge, pro-
vide for the first time extensive information regar-
ding the Polish population of patients diagnosed
with HF and hospitalized in cardiology and internal
medicine wards. The multicentre character of this
study allows the assumption that this data is repre-
sentative for the Polish population and that HF is
equally common among elderly men and women.
Coronary artery disease was the most common cau-
se of heart failure in the study group with hyper-
tension being second. Regardless of the type of
ward, decompensation of HF was the most common
cause of hospitalization. There have been an incre-
asing number of patients receiving ACEI and BB
treatment according to EVBM during hospitalization,
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including using both agents simultaneously, but
50% of patients still received less than  the recom-
mended dose. Compared with the assessment car-
ried out several years ago, there is a noticeable
improvement in the quality of standard-based HF
treatment. Nonetheless, dose optimalisation and
the avoidance of drugs with no positive effect on
prognosis in this population still remain unresolved
problems.
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